Pharma Mar, S.A. (BME:PHM)

Market Cap	1.33B
Revenue (ttm)	175.75M
Net Income (ttm)	19.88M
Shares Out	17.57M
EPS (ttm)	n/a
PE Ratio	66.72
Forward PE	22.87
Dividend	0.80 (1.08%)
Ex-Dividend Date	Jun 25, 2025

Volume	34,979
Average Volume	51,240
Open	73.05
Previous Close	73.95
Day's Range	72.95 - 75.45
52-Week Range	31.60 - 105.80
Beta	-0.06
RSI	46.29
Earnings Date	Apr 25, 2025

About Pharma Mar

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung ca...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1986
• Employees: 500
• Stock Exchange: Madrid Stock Exchange
• Ticker Symbol: PHM

Financial Performance

In 2024, Pharma Mar's revenue was 174.86 million, an increase of 10.56% compared to the previous year's 158.15 million. Earnings were 26.13 million, an increase of 2197.71%.